Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Accolade

Health Tech & Medtech · Plymouth Township, United States · Founded 2007 · IPO 2020 Unicorn

A personalized health and benefits solution that dramatically improves the experience, outcomes and cost of healthcare for employers, health plans and their members

Valuation
$576M
Market cap · 2026
Revenue
$414M
Latest reported FY

Investors

7 investors on Accolade's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage
Accretive
Humana
Series B+ 5 investors entered at this stage

Global footprint

Where Accolade has talent and traffic

AI talent share
0.6% of workforce is AI talent
(9 of 1,422 staff)
Core AI20.14%
Other AI70.49%
Non-AI workforce1,41399.37%
Workforce by country
19 countries with
team presence
🇺🇸 United States78.1%
🇨🇿 Czech Republic18.8%
🇨🇦 Canada1.6%
🇮🇹 Italy0.2%
🇧🇷 Brazil0.1%
Top 5 of 19 shown
Web traffic by country
130K monthly visits
across markets
🇺🇸 United States84.7%
🇨🇦 Canada7%
🇦🇺 Australia1.4%
🇬🇧 United Kingdom1.2%
🇮🇳 India1%
Top 5 markets shown

Patent intelligence

$2M patent portfolio · 4 active families

Estimated portfolio value
$2M
0.28% of market cap · 95.9× smaller than top peer Fitbit ($154M)
4 active patent families
Where Accolade innovates Computer scienceMedical treatmentSAPS IIPhysician referralInfection rate

Where Accolade concentrates vs peers

Each axis is a top-10 topic across Accolade and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Accolade's 3 investments and acquisitions.

Every disclosed deal where Accolade appeared as a backer or acquirer, 2019–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Accolade's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Accolade deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Accolade's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Accolade

        An AI-synthesized read of the highest-engagement posts about Accolade on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Accolade on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.